Maximilian Stahl, MD
Assistant ProfessorDownloadHi-Res Photo
Cards
Additional Titles
Instructor of Medicine
Contact Info
About
Titles
Assistant Professor
Instructor of Medicine
Departments & Organizations
- All Institutions
- Yale Medicine
Education & Training
- Post-doctoral Fellow
- Yale University (2014)
- MD
- Hannover Medical School (2013)
Board Certifications
Hematology (Internal Medicine)
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2021
Medical Oncology
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2021
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2017
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Maximilian Stahl's published research.
Publications Timeline
A big-picture view of Maximilian Stahl's research output by year.
Amer Zeidan, MBBS
Mina Xu, MD
Nikolai Podoltsev, MD, PhD
Alexa Siddon, MD
Christopher Bunick, MD, PhD
Juliette Fromm Spelman, MD, BS
13Publications
378Citations
Publications
2017
Hypomethylating agents in combination with histone deacetylase inhibitors in higher risk myelodysplastic syndromes: Is there a light at the end of the tunnel?
Stahl M, Zeidan AM. Hypomethylating agents in combination with histone deacetylase inhibitors in higher risk myelodysplastic syndromes: Is there a light at the end of the tunnel? Cancer 2017, 123: 911-914. PMID: 28094843, DOI: 10.1002/cncr.30532.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricMeSH Keywords and Concepts
2016
Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities
Stahl M, Kim TK, Zeidan AM. Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities. World Journal Of Stem Cells 2016, 8: 316-331. PMID: 27822339, PMCID: PMC5080639, DOI: 10.4252/wjsc.v8.i10.316.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricConceptsLeukemia stem cellsNormal hematopoietic stem cellsHematopoietic stem cellsAcute myeloid leukemia stem cellsMyeloid leukemia stem cellsStem cellsAcute myeloid leukemiaMultitude of drugsNovel therapeutic agentsCancer stem cellsClinical trialsMyeloid leukemiaTherapeutic windowSelf-renewal pathwaysXenograft modelClinical developmentTherapeutic opportunitiesRational targetTherapeutic agentsLSC biologyAcceptable therapeutic windowDrugsCellsFunctional studiesLeukemiaEpigenetics in Cancer: A Hematological Perspective
Stahl M, Kohrman N, Gore SD, Kim TK, Zeidan AM, Prebet T. Epigenetics in Cancer: A Hematological Perspective. PLOS Genetics 2016, 12: e1006193. PMID: 27723796, PMCID: PMC5065123, DOI: 10.1371/journal.pgen.1006193.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricMeSH Keywords and ConceptsConceptsEpigenetic mechanismsEpigenetic regulationNext-generation sequencingEpigenetic therapyCell agingAdvanced phase patientsEpigeneticsGeneration sequencingCancer cellsGenetic aberrationsPhase patientsClinical responseImmune responseHematological perspectiveProduction of drugsMyeloid malignanciesBody of dataCancerOncogenesisSequencingMechanismRegulationFateSelecting initial treatment of acute myeloid leukaemia in older adults
Podoltsev NA, Stahl M, Zeidan AM, Gore SD. Selecting initial treatment of acute myeloid leukaemia in older adults. Blood Reviews 2016, 31: 43-62. PMID: 27745715, DOI: 10.1016/j.blre.2016.09.005.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricMeSH Keywords and ConceptsConceptsAcute myeloid leukemiaTreatment-related mortalityInduction chemotherapyComplete remissionInitial treatmentMyeloid leukemiaNovel agentsOlder adultsMedian overall survivalGroup of patientsPhase III developmentDisease-related characteristicsMechanism of actionCPX-351Overall survivalLow-intensity treatmentClinical trialsTreatment outcomesPatientsRemissionChemotherapyLeukemiaMortalityTreatmentAdultsSingle agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia
Kim TK, Xu ML, Podoltsev NA, Prebet T, Barbarotta L, Amin K, Kasberg S, Roche K, Stahl M, Gore SD, Zeidan AM. Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia. Annals Of Hematology 2016, 95: 1895-1898. PMID: 27468851, PMCID: PMC10955604, DOI: 10.1007/s00277-016-2761-4.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsMeSH Keywords and ConceptsMeSH KeywordsAged, 80 and overAntibodies, BispecificAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBone MarrowBreast NeoplasmsCarcinoma, Transitional CellCytarabineFemaleHumansLymphoma, B-CellMercaptopurineMethotrexateNeoplasms, Second PrimaryPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrednisoneRemission InductionSalvage TherapyUrinary Bladder NeoplasmsVincristineTargeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitors
Stahl M, Gedrich R, Peck R, LaVallee T, Eder JP. Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitors. Immunotherapy 2016, 8: 767-774. PMID: 27349976, DOI: 10.2217/imt-2016-0040.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMyeloid-derived suppressor cellsInnate immune cellsCheckpoint inhibitorsSuppressor cellsImmune cellsMast cellsImmune checkpoint inhibitorsAntitumor immune responseImmune cell numbersReceptor tyrosine kinase KITDurable responsesMelanoma patientsClinical benefitTyrosine kinase KITCancer patientsPreclinical dataPoor survivalImmune responseSuppressive componentsImmune systemKIT inhibitorsTumor microenvironmentAntitumor activityKinase KITRecent evidenceImmune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy
Suozzi KC, Stahl M, Ko CJ, Chiang A, Gettinger SN, Siegel MD, Bunick CG. Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy. JAAD Case Reports 2016, 2: 264-268. PMID: 27486590, PMCID: PMC4949498, DOI: 10.1016/j.jdcr.2016.05.002.Peer-Reviewed Original ResearchCitationsAltmetricClinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia
Stahl M, Xu ML, Steensma DP, Rampal R, Much M, Zeidan AM. Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia. Annals Of Hematology 2016, 95: 1197-1200. PMID: 27068405, PMCID: PMC7479634, DOI: 10.1007/s00277-016-2664-4.Peer-Reviewed Original ResearchMulti‐system complications of hypereosinophilia
Stahl M, Mohareb AM, Lee AI, Federman DG, Siddon AJ, Spelman J. Multi‐system complications of hypereosinophilia. American Journal Of Hematology 2016, 91: 444-447. PMID: 26700720, DOI: 10.1002/ajh.24283.Peer-Reviewed Original ResearchCitationsAltmetricLost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes
Stahl M, Gore SD, Vey N, Prebet T. Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Expert Opinion On Investigational Drugs 2016, 25: 307-317. PMID: 26807602, DOI: 10.1517/13543784.2016.1146251.BooksCitationsAltmetricMeSH Keywords and ConceptsConceptsHistone deacetylase inhibitorsAcute myeloid leukemiaMyeloid malignanciesMyelodysplastic syndromeMyeloid leukemiaDeacetylase inhibitorsSelection of patientsFuture clinical developmentClinical resultsDNA methyltransferase inhibitorClinical developmentSingle agentHDAC inhibitorsRobust biomarkersPleiotropic activitiesMalignancyPotential targetCancer therapyMethyltransferase inhibitorSyndromeLeukemiaInhibitorsEpigenetic modifiersEpigenetic changesMyeloma
News
News
- March 19, 2018Source: Healio
Pacritinib reduces splenomegaly, symptoms in myelofibrosis
- December 09, 2017Source: Healio
Immunosuppressive therapy leads to transfusion independence for nearly 40% of patients with myelodysplastic syndrome
- March 10, 2017Source: Clinical Oncology News
Hypomethylating Agents Can Extend AML OS for Some
- December 04, 2016
Alternative Option to Intensive Chemotherapy for Patients with relapsed/refractory Acute Myeloid Leukemia (AML)